¼¼°èÀÇ ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : Á¦Ç° Á¾·ùº°, Ä¡·á ºÐ¾ßº°, Á¦Á¶ ±Ô¸ðº°, ¿öÅ©ÇÃ·Î¿ì ´Ü°èº°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Lentiviral Vectors Market, By Product Type, By Therapeutic Area, By Manufacturing Scale, By Workflow Stage, By Application, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1756396
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 298 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,474,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,401,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,778,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍÀÇ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 1¾ï 7,010¸¸ ´Þ·¯·Î 2025³âºÎÅÍ 2032³â±îÁö 11.92%ÀÇ CAGR·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå ¿ªÇÐ

À¯ÀüÀÚ µµÀÔ ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍÀÇ Ã¤Åà °¡¼ÓÈ­

À¯ÀüÀÚ µµÀÔ ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ´Â Àü ¼¼°èÀûÀ¸·Î Ä¡·á ¹× ¿¬±¸ ºÐ¾ß¿¡¼­ ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³¾Ï¿¬±¸¼Ò(NCI)ÀÇ º¸°í¿¡ µû¸£¸é ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ´Â CAR-T ¼¼Æ÷ Ä¡·áÀÇ ÇÙ½ÉÀ̸ç, FDA°¡ ½ÂÀÎÇÑ ÀϺΠġ·á¹ýÀº Ç¥Àû ¾Ï Ä¡·á¸¦ À§ÇØ È¯ÀÚÀÇ ¸é¿ª¼¼Æ÷¸¦ º¯Çü½Ã۱â À§ÇØ ·»Æ¼¹ÙÀÌ·¯½º º¤Å͸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)Àº ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍÀÇ ¾ÈÀü¼º°ú È®À强À» °³¼±ÇÏ°í »ðÀÔÇü µ¹¿¬º¯ÀÌ À¯¹ß¿¡ ´ëÇÑ ¿ì·Á¸¦ ÇØ°áÇϱâ À§ÇØ ¿©·¯ ÇÁ·Î±×·¥¿¡ ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â EMA¿Í °°Àº ±ÔÁ¦ ±â°üÀÌ ·»Æ¼¹ÙÀÌ·¯½º¸¦ ÀÌ¿ëÇÑ À¯ÀüÀÚ Ä¡·áÀÇ ÀÓ»ó½ÃÇè ½ÂÀÎÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ·»Æ¼¹ÙÀÌ·¯½ºÀÇ °¡´É¼º¿¡ ´ëÇÑ ½Å·Ú°¡ ³ô¾ÆÁ³À½À» ¹Ý¿µÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº À¯ÀüÀÚ µµÀÔ ±â¼úÀÇ °­È­°¡ ¸ÂÃãÇü ÀÇ·áÀÇ ¹üÀ§¸¦ È®ÀåÇϰí À¯Àü¼º ¹× ÈÄõ¼º Áúȯ¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀ» ¹ßÀü½ÃŰ´Â µ¥ ÀÖ¾î Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀÓÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 11.92%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â ·»Æ¼¹ÙÀÌ·¯½º Æ÷Àå ½Ã½ºÅÛÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµÆ½À´Ï´Ù.

Ä¡·á ºÐ¾ßº°·Î´Â ¾ÏÀÌ 2024³â ÁÖ¿ä Ä¡·á ¿µ¿ªÀ¸·Î ²ÅÇû½À´Ï´Ù.

Á¦Á¶ ±Ô¸ðº°·Î´Â 2024³â ÀÓ»ó µî±ÞÀÌ ÁÖ¿ä Á¦Á¶ ±Ô¸ð¿¡ ÇØ´çÇÕ´Ï´Ù.

¿öÅ©ÇÃ·Î¿ì ´Ü°èº°·Î´Â 2024³â ¹ÙÀÌ·¯½º ÆÐŰ¡ÀÌ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù.

¿ëµµº°·Î´Â ¼¼Æ÷ Ä¡·áÁ¦(CAR-T µî)°¡ 2024³â ÁÖ¿ä ¿ëµµ¿´½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ¼¼°è ½ÃÀåÀº Á¦Ç° À¯Çü, Ä¡·á ¿µ¿ª, Á¦Á¶ ±Ô¸ð, ¿öÅ©ÇÃ·Î¿ì ´Ü°è, ¿ëµµ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çü¿¡ µû¶ó 6°¡Áö Ä«Å×°í¸®·Î ³ª´¹´Ï´Ù. ·»Æ¼¹ÙÀÌ·¯½º ÆÐŰ¡ ½Ã½ºÅÛ, ·»Æ¼¹ÙÀÌ·¯½º Çö󽺹̵å, ¸ÂÃãÇü ·»Æ¼¹ÙÀÌ·¯½º »ý»ê ¼­ºñ½º, Áï½Ã »ç¿ë °¡´ÉÇÑ ·»Æ¼¹ÙÀÌ·¯½º, ·»Æ¼¹ÙÀÌ·¯½º ÇÁ·Î¸ðÅÍ, ·»Æ¼¹ÙÀÌ·¯½º Ç»Àü ű×ÀÔ´Ï´Ù. ·»Æ¼¹ÙÀÌ·¯½º ÆÐŰ¡ ½Ã½ºÅÛÀº º¤ÅÍ ¾î¼Àºí¸®¿¡¼­ÀÇ ¿ªÇÒ·Î ÀÎÇØ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ·»Æ¼¹ÙÀÌ·¯½º Çö󽺹̵å´Â À¯ÀüÀÚ º¹Á¦¿¡ ÇʼöÀûÀÔ´Ï´Ù.

½ÃÀåÀº Ä¡·á ¿µ¿ª¿¡ µû¶ó 4°¡Áö Ä«Å×°í¸®·Î ³ª´¹´Ï´Ù. ¾Ï, Èñ±ÍÁúȯ, °¨¿°Áúȯ, ½Å°æÁúȯÀÔ´Ï´Ù. Èñ±ÍÁúȯÀº ¸ÂÃã À¯ÀüÀÚ Ä¡·áÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖÀ¸¸ç, ½Å°æÁúȯÀº À¯ÀüÀÚ ÆíÁý°ú º¤ÅÍ Àü´Þ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ´Â »õ·Î¿î Ÿ°ÙÀÔ´Ï´Ù.

·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : Áö¿ªº° ºÐ¼®

·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀåÀº Áö¿ªº°·Î Å« Â÷À̸¦ º¸À̰í ÀÖÀ¸¸ç, ºÏ¹Ì´Â Àß ±¸ÃàµÈ ¹ÙÀÌ¿ÀÀǾàǰ ÀÎÇÁ¶ó, À¯ÀüÀÚ Ä¡·á ¿¬±¸¿¡ ´ëÇÑ È°¹ßÇÑ ÀÚ±Ý Áö¿ø, FDA¸¦ Áß½ÉÀ¸·Î ÇÑ ±ÔÁ¦ ȯ°æÀÇ Áö¿øÀ¸·Î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ƯÈ÷ CAR-T ¼¼Æ÷ Ä¡·áÁ¦ ¹× Èñ±Í À¯Àü¼º Áúȯ¿¡¼­ ·»Æ¼¹ÙÀÌ·¯½º º¤Å͸¦ ÀÌ¿ëÇÑ ÀÓ»ó½ÃÇèÀÌ ¸¹ÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º µîÀÇ ±¹°¡µéÀÌ À¯ÀüÀÚ Ä¡·á ±â¼ú Çõ½Å¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, À¯·´ÀǾàǰûÀÇ °£¼ÒÈ­µÈ ±ÔÁ¦ °æ·ÎÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹, ÀϺ», Çѱ¹ µîÀÇ ±¹°¡¿¡¼­ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿Í ¼¼Æ÷ Ä¡·á ÇÁ·Î±×·¥ ÃßÁøÀ» À§ÇÑ Á¤ºÎÀÇ ³ë·ÂÀÌ È°¹ßÇØÁü¿¡ µû¶ó ºü¸£°Ô ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±¹°¡¿¡¼­´Â Çаè¿Í ¹ÙÀÌ¿ÀÅØ ±â¾÷°úÀÇ °øµ¿ °³¹ßÀÌ È°¹ßÇØÁö¸é¼­ ·»Æ¼¹ÙÀÌ·¯½º º¤Å͸¦ ÀÌ¿ëÇÑ Ä¡·á¹ýÀÇ ÀÓ»ó °³¹ß ¹× »ó¿ëÈ­°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí, ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿Àº Áö¿ª À¯Àü¼º Áúȯ ´ëÀÀ°ú ÀÇ·á Á¢±Ù¼º °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÆÄÆ®³Ê½Ê°ú ÀÎÇÁ¶ó °³¹ßÀ» ÅëÇØ Á¡Â÷ ¿ª·®À» È®´ëÇϰí ÀÖ½À´Ï´Ù.

·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : °æÀï »óȲ

·»Æ¼Å§·¯ ¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀåÀÇ °æÀï ±¸µµ´Â ±âÁ¸ »ý¸í°øÇÐ ±â¾÷, ½Å»ý º¥Ã³±â¾÷, À¯ÀüÀÚ µµÀÔ ±â¼ú ¹ßÀü¿¡ ÁÖ·ÂÇÏ´Â Çмú ¿¬±¸±â°üÀÇ Á¶ÇÕÀ¸·Î Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº À¯ÀüÀÚ µµÀÔ È¿À²À» ³ôÀÌ°í »ðÀÔ µ¹¿¬º¯ÀÌ À¯¹ß À§ÇèÀ» ÁÙÀ̱â À§ÇØ º¸´Ù ¾ÈÀüÇϰí È¿À²ÀûÀÎ ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ Ç÷§Æû °³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÁ¦¾à±â¾÷°ú Çмú¼¾ÅÍ¿ÍÀÇ Àü·«Àû Á¦ÈÞ ¹× ¶óÀ̼±½Ì °è¾àÀÌ ÀϹÝÈ­µÇ¾î ºü¸¥ ±â¼ú Çõ½Å°ú ÀÓ»ó Àû¿ëÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ±â¾÷µéÀº ¶ÇÇÑ ÀÓ»ó¿ë ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ »ý»ê´É·ÂÀ» È®ÀåÇϰí, È®À强°ú ±ÔÁ¦ Áؼö¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚ°¡ ºÒȰ¼ºÈ­ º¤ÅÍ, Ç¥Àû Àü´Þ ½Ã½ºÅÛ µî Ä¡·á È¿°ú¸¦ ³ôÀ̱â À§ÇÑ »õ·Î¿î º¤ÅÍ ¿£Áö´Ï¾î¸µ ±â¼ú °³¹ß ³ë·ÂÀ¸·Î °æÀïÀÌ ½ÉÈ­µÇ°í ÀÖ½À´Ï´Ù. ÁöÀûÀç»ê±Ç °ü¸®¿Í µ¶Á¡Àû ±â¼ú ±Ç¸® È®º¸´Â ÁøÈ­ÇÏ´Â ÀÌ ºÐ¾ß¿¡¼­ ½ÃÀå ÁöÀ§¸¦ À¯ÁöÇϰí Àå±âÀûÀÎ ¼ºÀåÀ» ÃËÁøÇϱâ À§ÇØ °è¼Ó Áß¿äÇÏ°Ô ÀÛ¿ëÇÒ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå »óȲ

Á¦7Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : Á¦Ç° Á¾·ùº°

Á¦8Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : Ä¡·á ºÐ¾ßº°

Á¦9Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : Á¦Á¶ ±Ô¸ðº°

Á¦10Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : ¿öÅ©ÇÃ·Î¿ì ´Ü°èº°

Á¦11Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : ¿ëµµº°

Á¦12Àå ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ½ÃÀå : Áö¿ªº°

Á¦13Àå ÁÖ¿ä º¥´õ ºÐ¼® : ·»Æ¼¹ÙÀÌ·¯½º º¤ÅÍ ¾÷°è

Á¦14Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Lentiviral Vectors Market size was valued at US$ 170.10 Million in 2024, expanding at a CAGR of 11.92% from 2025 to 2032.

The Lentiviral Vectors Market involves the development and use of lentivirus-based delivery systems primarily for gene therapy, vaccine development, and research applications. Increasing demand for effective gene delivery methods in treating genetic disorders and cancers has expanded the use of lentiviral vectors, which are favored for their ability to integrate into host genomes and provide stable, long-term gene expression. In 2023, over 60% of gene therapy clinical trials incorporated lentiviral vectors to enhance therapeutic outcomes. However, challenges like high manufacturing costs, biosafety concerns, and potential insertional mutagenesis limit widespread adoption. Advances in vector engineering and scalable production methods offer promising opportunities to improve safety profiles and reduce costs. Additionally, growing investments in CAR-T cell therapies and immunotherapy research present significant avenues for market expansion as lentiviral vectors play a crucial role in modifying immune cells for targeted treatments.

Lentiviral Vectors Market- Market Dynamics

Advancements in gene delivery systems to accelerate lentiviral vector adoption

Advancements in gene delivery systems are accelerating the adoption of lentiviral vectors in therapeutic and research applications worldwide. The National Cancer Institute (NCI) reports that lentiviral vectors have become a cornerstone in CAR-T cell therapies, with several FDA-approved treatments utilizing these vectors to modify patients' immune cells for targeted cancer treatment. Additionally, the U.S. National Institutes of Health (NIH) has funded multiple programs aimed at improving lentiviral vector safety and scalability, addressing concerns related to insertional mutagenesis. In Europe, regulatory agencies such as the EMA have facilitated clinical trial approvals for lentiviral-based gene therapies, reflecting growing confidence in their potential. These efforts underscore the critical role of enhanced gene delivery technologies in expanding the reach of personalized medicine and advancing treatment options for genetic and acquired diseases.

Lentiviral Vectors Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.92% over the forecast period (2025-2032)

Based on product type segmentation, Lentiviral Packaging Systems was predicted to show maximum market share in the year 2024

Based on Therapeutic Area segmentation, Cancer was the leading Therapeutic Area in 2024

Based on Manufacturing Scale segmentation, Clinical Grade was the leading Manufacturing Scale in 2024

Based on Workflow Stage segmentation, Viral Packaging was the leading Workflow Stage in 2024

Based on Application segmentation, Cell Therapy (e.g., CAR-T) was the leading Application in 2024

On the basis of region, North America was the leading revenue generator in 2024

Lentiviral Vectors Market- Segmentation Analysis:

The Global Lentiviral Vectors Market is segmented on the basis of Product Type, Therapeutic Area, Manufacturing Scale, Workflow Stage, Application, and Region.

The market is divided into six categories based on product type: Lentiviral Packaging Systems, Lentiviral Plasmids, Custom Lentivirus Production Services, Ready-to-use Lentivirus, Lentiviral Promoter, and Lentiviral Fusion Tags. Lentiviral Packaging Systems dominate due to their role in vector assembly; Lentiviral Plasmids are essential for gene cloning; Custom Lentivirus Production Services offer tailored solutions; Ready-to-use Lentivirus provides convenience; Lentiviral Promoters and Fusion Tags support gene expression and protein tracking.

The market is divided into four categories based on Therapeutic Area: Cancer, Rare Diseases, Infectious Diseases, and Neurological Disorders. Cancer leads as the primary therapeutic area due to extensive CAR-T applications; Rare Diseases benefit from personalized gene therapies; Infectious Diseases see growing vector use for vaccine development; Neurological Disorders are emerging targets with increasing research in gene editing and vector delivery.

Lentiviral Vectors Market- Geographical Insights

The Lentiviral Vectors Market shows significant regional variation, with North America leading due to its well-established biopharmaceutical infrastructure, robust funding for gene therapy research, and supportive regulatory environment led by the FDA. The U.S. hosts numerous clinical trials utilizing lentiviral vectors, particularly in CAR-T cell therapies and rare genetic disorders. Europe is also a key player, with countries like Germany, the UK, and France investing heavily in gene therapy innovation and benefiting from the European Medicines Agency's streamlined regulatory pathways. The Asia-Pacific region is rapidly emerging, driven by increased government initiatives in China, Japan, and South Korea to advance biotechnology and cell therapy programs. Growing collaborations between academic institutions and biotech firms in these countries are accelerating clinical development and commercialization of lentiviral vector-based therapies. Meanwhile, Latin America and the Middle East are gradually expanding their capabilities through partnerships and infrastructure development, focusing on addressing regional genetic disorders and improving healthcare access.

Lentiviral Vectors Market- Competitive Landscape:

The competitive landscape of the Lentiviral Vectors Market is shaped by a combination of established biotechnology companies, emerging startups, and academic research institutions focused on advancing gene delivery technologies. Leading players are investing in the development of safer, more efficient lentiviral vector platforms to improve transduction efficiency and reduce insertional mutagenesis risks. Strategic collaborations and licensing agreements between biopharma companies and academic centers are common, enabling rapid innovation and clinical translation. Companies are also expanding manufacturing capabilities to meet growing demand for clinical-grade lentiviral vectors, emphasizing scalability and regulatory compliance. Additionally, competition is intensified by efforts to develop novel vector engineering techniques, such as self-inactivating vectors and targeted delivery systems, to enhance therapeutic efficacy. Intellectual property management and securing exclusive rights to proprietary technologies remain critical for maintaining market position and fostering long-term growth in this evolving sector.

Recent Developments:

In June 2024, Charles River Laboratories announced a strategic collaboration with the Gates Institute at University of Colorado Anschutz to manufacture lentiviral vectors, accelerating CAR-T cell therapy development for hematological cancers and enhancing advanced cell and gene therapy manufacturing capabilities.

In September 2024, Rentschler Biopharma launched lentiviral vector manufacturing services at its Stevenage, UK facility, introducing a new LVV toolbox to complement existing AAV vector offerings and accelerate advanced therapy development for gene and cell therapy applications, including rare diseases and cancer immunotherapy.

In April 2025, ViroCell Biologics manufactured a GMP lentiviral vector for UCL's clinical trial, accelerating innovative CAR T-cell therapy development for relapsed paediatric acute lymphoblastic leukaemia, with the first patient enrolled in March 2025, aiming to prevent relapse in childhood blood cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LENTIVIRAL VECTORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL LENTIVIRAL VECTORS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL LENTIVIRAL VECTORS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

GLOBAL LENTIVIRAL VECTORS MARKET, BY MANUFACTURING SCALE- MARKET ANALYSIS, 2019 - 2032

GLOBAL LENTIVIRAL VECTORS MARKET, BY WORKFLOW STAGE- MARKET ANALYSIS, 2019 - 2032

GLOBAL LENTIVIRAL VECTORS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL LENTIVIRAL VECTORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Lentiviral Vectors Market Overview

2. Executive Summary

3. Lentiviral Vectors Key Market Trends

4. Lentiviral Vectors Industry Study

5. Lentiviral Vectors Market: Impact of Escalating Geopolitical Tensions

6. Lentiviral Vectors Market Landscape

7. Lentiviral Vectors Market - By Product Type

8. Lentiviral Vectors Market - By Therapeutic Area

9. Lentiviral Vectors Market - By Manufacturing Scale

10. Lentiviral Vectors Market - By Workflow Stage

11. Lentiviral Vectors Market - By Application

12. Lentiviral Vectors Market- By Geography

13. Key Vendor Analysis- Lentiviral Vectors Industry

14. 360 Degree Analyst View

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â